In a report released on January 15, Nik Modi from RBC Capital maintained a Hold rating on Colgate-Palmolive (CL – Research Report), with a

BMO Capital Markets forecasts the S&P 500 will reach 6,700, reflecting a gain of 13.2%. Chief investment strategist Brian Belski said he and his team "remain resolutely bullish," but expect "performance and fundamentals will more closely match the historical norms -- namely, in the high-single digit/low-double-digit percentage range in 2025."

RBC Capital Markets adjusted its price target for Westlake Chemical (NYSE:WLK) stock, reducing it to $147.00 from the previous $167.00, yet the firm retained its Outperform rating on the shares. The revision follows a review of the company's financial outlook,

RBC Capital analyst Nik Modi maintained a Buy rating on Spectrum Brands Holdings (SPB – Research Report) on January 15 and set a price target

Shares of UBS Group stock opened at $32.31 on Friday. The company has a debt-to-equity ratio of 3.87, a quick ratio of 1.05 and a current ratio of 1.05. UBS Group has a fifty-two week low of $26. ...

Street Talk understands Hong Kong’s Chow Tai Fook has tapped investment banks UBS and RBC Capital Markets for advice. How much Alinta’s owners are looking to part with is unclear, but Chow Tai ...

UBS downgraded Goldman Sachs (NYSE:GS) to Neutral from Buy as the Wall Street firm's business model relies heavily on Global Banking & Markets ("GBM"), and a "considerable" capital markets ...

UBS Emerging Markets Equity Opp Fund earns an Average ... The investment seeks to maximize capital appreciation. Under normal circumstances, the fund invests at least 80% of its net assets ...

Shawn Marie Soderberg, Chief Legal Officer and Corporate Secretary of Bloom Energy Corp (NYSE:BE), a $5.5 billion market cap clean energy company whose stock has surged 109% over the past year, has disclosed the sale of company stock,

In a challenging market environment, Ideaya Biosciences Inc . (NASDAQ:IDYA) stock has reached its 52-week low, trading at $22.15. The biotechnology firm, which specializes in precision medicine oncology,

Oil Headed for Weekly Gains on Supply Disruption Fears -- Market Talk

BMO Capital Markets has recently reduced Exelixis Inc (EXEL) stock to Market Perform rating, as announced on December 20, 2024, according to Finviz. Earlier, on December 17, 2024, BofA Securities had reduced the stock from a Buy to Neutral,